Table 3. Summary of clinical efficacy and adverse event in phase 2a trial.

Patients ID	Dose (mg)	Cytology			Histology			AEs
		Baseline	16 week	Response	Baseline	16 week	Response
2-1 (D0201)	1,000	HSIL	HSIL	No interval change	CIN 3	CIN 3	No interval change	Nasopharyngitis
2-2 (D0401)	1,000	ASC-US	ASC-H	Progression	CIN 3	CIN 1	Regression	None
2-3 (D0402)	1,000	ASC-US	ASC-US	No interval change	CIN 3	CIN 1	Regression	None
2-5 (D0502)	1,000	Negative	Negative	No interval change	CIN 3	Normal	Remission	Headache
2-6 (D0503)	1,000	ASC-H	Negative	Remission	CIN 3	Normal	Remission	Headache
2-7 (D0504)	1,000	ASC-US	Negative	Remission	CIN 3	Normal	Remission	Abdominal pain lower, Ileus
2-8 (D0505)	1,000	ASC-H	Negative	Remission	CIN 3	CIN 1	Regression	None
2-9 (D0506)	1,000	LSIL	HSIL	Progression	CIN 3	CIN 3	-	Psoriasis

AE, adverse event; ASC-H, atypical squamous cells, cannot exclude; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; LSIL, Low-grade squamous intraepithelial lesion.